Associations between gut microbiota and osteoporosis or osteopenia in a cohort of Chinese Han youth
September 9, 2024 / Bone Density / Gut Bacteria / Bone Health
A study of Chinese Han youth revealed significant differences in gut microbiota composition between osteoporosis, osteopenia, and normal bone density groups. Key genera like Faecalibacterium and Bacteroides were associated with bone mineral density variations.
Multi-omics study unravels gut microbiota and metabolites alteration in patients with Wilson’s disease
September 9, 2024 / Wilson’s Disease / Gut Microbiota
A multi-omics study in Wilson’s disease (WD) patients revealed gut microbiota imbalances and altered metabolites, including reduced bacterial diversity and key protective metabolites. This research suggests new microbial and metabolic targets for potential WD therapies.
New insight into primary hyperparathyroidism using untargeted metabolomics
September 9, 2024 / Cardiovascular Complications / Oxidative Stress / Hyerparathyroidism
An untargeted metabolomics study revealed distinct metabolic imbalances in primary hyperparathyroidism (PHPT) patients, including altered amino acids, gamma-glutamyls, and sphingosine-1-phosphate, linked to oxidative stress, cardiovascular complications, and reduced bone mineral density.
Night owls are more likely to develop diabetes, study says — but a simple lifestyle change may help
September 8, 2024 / Type 2 Diabetes Risk / Metabolic Health / Night Owls
Night owls have a 46% higher risk of developing Type 2 diabetes due to circadian misalignment, visceral fat accumulation, and metabolic disturbances. Adjusting meal timing may help improve metabolic health in those with a late chronotype.
Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease
September 8, 2024 / Biomarkers / Muscle Degeneration Diagnostic Tools / Clinical Study
A clinical study using multispectral optoacoustic tomography (MSOT) demonstrates its higher sensitivity in detecting muscle degeneration in late-onset Pompe disease (LOPD) by imaging glycogen, collagen, and lipid changes, offering a non-invasive alternative to current diagnostic methods.
Association between the weight-adjusted-waist index and circadian syndrome in findings from a nationwide study
September 6, 2024 / Weight-adjusted waist index / Circadian Syndrome / Obesity / Metabolic Health
A nationwide study found a significant positive association between the Weight-Adjusted Waist Index (WWI) and circadian syndrome (CircS). Managing central obesity, as measured by WWI, is crucial for preventing or mitigating CircS, which involves metabolic disruptions.
Weight-loss surgery may help people with obesity better manage high blood pressure
September 5, 2024 / Bariatric Surgery / Hypertension / Cardiovascular Health
Bariatric surgery significantly improves long-term blood pressure control in people with obesity, reducing dependence on medications and lowering cardiovascular disease risk, according to a new analysis of 18 randomized controlled trials.
Low-carb diets exceed nutrient needs and promote heart health by improving key dietary ratios
September 5, 2024 / Low-carb / Heart Health / Metabolic Disease
A study published in Frontiers in Nutrition shows that low-carb diets, despite varying carbohydrate levels, meet or exceed nutrient needs and improve heart health by enhancing dietary fiber intake and balancing macronutrient ratios.
Lilly to collaborate with Haya Therapeutics to develop drugs for metabolic conditions
September 5, 2024 / Eli-Lilly / Haya Therapeutics / RNA / Obesity
Eli Lilly will work with RNA-focused Haya Therapeutics to search for new targets to develop drugs for metabolic conditions such as obesity.
Duke professor’s research leads to first drug for type of liver disease
September 5, 2024 / MASH Treatment / FDA / Metabolic Liver Disease
Duke professor Paul Yen’s research led to the development of resmetirom, the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease linked to obesity. The drug targets liver fat buildup, reducing progression to cirrhosis.
Low-carb/high-fat diets for weight loss may actually boost risk of type 2 diabetes
September 5, 2024 / Low-carb Diabetes Risk / Obesity
A 17-year study found that low-carb, high-fat diets increase the risk of developing type 2 diabetes by 20%, likely due to increased obesity. A balanced, fiber-rich diet with healthy fats may be better for diabetes prevention.
Tirzepatide for Diabetes Tied to Lower Mortality, Cardiorenal Risk Than GLP-1RAs
September 5, 2024 / Tirzepatide / GLP-1 / Diabetes Treatment / Cardiorenal Benefits / Kidney Health / Diabetes Treatment
Tirzepatide treatment for type 2 diabetes reduces mortality, cardiovascular, and kidney risks more effectively than GLP-1 receptor agonists, according to a JAMA Network Open study. It also improves HbA1c levels and body weight outcomes.
Plant-Based Diets Improve Cardiometabolic Health
September 5, 2024 / Cardiovascular Risk / Plant-based Diet / Blood Pressure / Weight Management
A cohort study in India found that adults on a predominantly plant-based diet had lower risks of cardiovascular events, reduced blood pressure, LDL cholesterol, and body weight, compared to those on animal-based or mixed diets.
Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity
September 5, 2024 /Metabolic Syndrome / Cardiovascular-Kidney-Metabolic Health / Obesity
A preclinical study using a canine model replicated key features of metabolic syndrome (MetS) independent of obesity, highlighting cardiovascular, metabolic, and renal changes. This model supports future research on antidiabetic therapies beyond glucose reduction.
Ochsner Digital Medicine elevates program with a focus on total cardiometabolic health
September 4, 2024 / Ochsner Digital Medicine / Weight Management / Cardiometabolic Care Program / Cardiometabolic Health
Ochsner Digital Medicine has expanded its cardiometabolic care program to include comprehensive weight management. This personalized, holistic approach offers tailored care, including GLP-1 therapy, for conditions like obesity, hypertension, diabetes, and hyperlipidemia.
How rival weight-loss drugs fare at treating obesity, diabetes and more
September 3, 2024 / GLP-1 / Weight Loss / Tirzepatide / Semaglutide / Obesity / Diabetes
New GLP-1 and GIP receptor-targeting drugs like semaglutide and tirzepatide show varying effects on obesity, diabetes prevention, and cardiovascular disease, while older GLP-1 drugs may offer benefits in treating neurodegenerative conditions like Parkinson’s and Alzheimer’s disease.
Nonalcoholic fatty liver disease and gut-liver axis: Role of intestinal microbiota and therapeutic mechanisms
September 3, 2024 / MASLD / NAFLD / Liver Disease
Nonalcoholic fatty liver disease (MASLD) is driven by metabolic dysfunction and linked to gut microbiota imbalances. Therapies targeting the gut-liver axis, like fecal microbiota transplantation and prebiotics, offer promising treatment strategies for MASLD progression and management.
AHA announces new initiative for cardiovascular kidney metabolic syndrome
September 3, 2024 / Cardiovascular Kidney Metabolic Syndrome / Early Detection
The American Heart Association’s 4-year initiative aims to establish clinical guidelines for cardiovascular kidney metabolic (CKM) syndrome, a newly defined disorder linking heart, kidney, metabolic diseases, and obesity to improve early detection, integrated care, and patient outcomes.
Exposure to ‘forever chemicals’ during pregnancy might raise long-term obesity risk
September 6, 2024 / Obesity Risk / Weight Gain / Health Impact
A study found that higher PFAS exposure during early pregnancy is linked to long-term weight gain and increased body fat in women at age 50, raising the risk of obesity and cardiovascular issues later in life.